Connect your AI

Precigen PGEN Change in Other Liabilities

Change in Other Liabilities at other companies

CRISPR TherapeuticsCRSP

-$199K+98.1%

BridgeBio PharmaBBIO

$4.62M+56.8%

Roivant SciencesROIV

-$252K-230%

AmgenAMGN

-$75M+3.8%

Merck & Co.MRK

$48.75M+498%

Other financials

Income statement

Revenue$23.3M+1,634%

Operating income-$6.0M+73.5%

Net income-$7.9M+85.4%

EPS (diluted)-$0.02+88.9%

Balance sheet

Cash & equivalents$7.5M+23.5%

Total debt$98.3M+1,714%

Total equity$20.2M+244%

Total assets$138.6M+7.6%

Cash flow

Operating cash flow-$43.8M-168%

CapEx$258.0K-58.5%

Free cash flow-$44.1M-160%

Valuation

Market cap$1.91B+213%

Enterprise value$2B+234%

P/S72×—

Profitability

Gross margin83.6%—

Operating margin-2,890.9%—

Net margin-3,656%—

FCF margin-1,756.5%—

Returns & leverage

Return on equity-843.6%-1,103pp

Debt / equity4.9×—

Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's change in other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Precigen's change in other liabilities?: Precigen (PGEN) reported change in other liabilities of -$28K in Q1 2026.
What does change in other liabilities mean?: Change in miscellaneous liabilities affecting operating cash flow.